These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 2482025)

  • 21. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial.
    Johnson TM; Jones K; Williford WO; Kutner MH; Issa MM; Lepor H
    J Urol; 2003 Jul; 170(1):145-8. PubMed ID: 12796667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
    Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
    J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
    Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
    Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group.
    Brawer MK; Adams G; Epstein H
    Arch Fam Med; 1993 Sep; 2(9):929-35. PubMed ID: 7509243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of terazosin on functional bladder outlet obstruction in women: a pilot study.
    Kessler TM; Studer UE; Burkhard FC
    J Urol; 2006 Oct; 176(4 Pt 1):1487-92. PubMed ID: 16952666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates.
    Lepor H; Nieder A; Feser J; O'Connell C; Dixon C
    Urology; 1997 Mar; 49(3):476-80. PubMed ID: 9123722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention].
    Yang C; Li YL; Fang J; Zhang X; Liu HP; Qin XH; Xu XP
    Zhonghua Nan Ke Xue; 2009 May; 15(5):441-4. PubMed ID: 19514558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The use of terazosin hydrochloride (Hytrin) in the treatment of patients with benign prostatic hyperplasia].
    Sivkov AV; Apolikhin OI; Medvedev AA
    Urol Nefrol (Mosk); 1997; (5):50-3. PubMed ID: 9412019
    [No Abstract]   [Full Text] [Related]  

  • 29. [Clinical effectiveness and safety study of combined therapy with an alpha-blocker and an anticholinergic for patients with LUT/BPH].
    Xiao H; Li HZ; Yang Y; Huang ZM; Li YQ; Zhao XF
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(23):1590-3. PubMed ID: 17803845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Terazosin, finasteride, or both in benign prostatic hyperplasia.
    Kuchel GA; DuBeau CE; Resnick NM
    N Engl J Med; 1997 Jan; 336(4):293-4; author reply 294. PubMed ID: 9005317
    [No Abstract]   [Full Text] [Related]  

  • 31. Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia.
    Witjes WP; Rosier FW; de Wildt MJ; van Iersel MP; Debruyne FM; de La Rosette JJ
    J Urol; 1996 Apr; 155(4):1317-23. PubMed ID: 8632523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
    Pushkar' DIu; Kosko DV; Loran OB; Kan IaD; Sapozhnikov IM; Tevlin KP
    Urol Nefrol (Mosk); 1995; (4):32-5. PubMed ID: 7571199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia.
    Lepor H; Knapp-Maloney G; Sunshine H
    J Urol; 1990 Dec; 144(6):1393-7; discussion 1397-8. PubMed ID: 1700152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD
    Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Terazosin vs finasteride for BPH.
    Zacks M
    J Fam Pract; 1996 Dec; 43(6):533. PubMed ID: 8969692
    [No Abstract]   [Full Text] [Related]  

  • 37. [Use of terazosin and alfuzosin in the treatment of benign prostatic hypertrophy (BPH): our experience].
    Larosa M; Ferretti S; Salsi P; Simonazzi M
    Acta Biomed Ateneo Parmense; 1994; 65(1-2):23-8. PubMed ID: 7528458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The management of symptomatic benign prostatic hyperplasia with the once-daily alpha 1 blocker, terazosin.
    Woods AL
    Mil Med; 1992 Jul; 157(7):361-4. PubMed ID: 1382248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapy of benign prostatic hyperplasia with alpha receptor blockers].
    Stockamp K
    Urologe A; 1995 Jan; 34(1):3-8. PubMed ID: 7533449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia.
    Tsujii T
    Int J Urol; 2000 Jun; 7(6):199-205. PubMed ID: 10843450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.